Bremer B, Anastasiou OE, Hardtke S, et al. - Researchers conducted the study for analyzing the role of low levels of HDV‐RNA during and after interferon therapy of hepatitis D. They re‐analysed HDV RNA in 372 samples obtained in the HIDIT‐2 trial with the Robogene assay. HDV-RNA was observed in one-third of samples previously classified as undetectable using a highly sensitive RA. A high risk for post-treatment relapse, identified as HDV RNA positivity in both assays at week 120, was associated with low HDV viraemia detectable at week 48 or week 96. In 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96, HDV RNA relapses occurred. Conversely, in patients with undetectable HDV RNA in both assays during treatment, the post-treatment relapse rate was lower.